1.1.1.64	drug target	since 17beta-HSD3 plays a central role in testosterone production, it is a promising therapeutic target to reduce the circulating level of androgens and to suppress androgen-sensitive tumor proliferation	762479	
1.1.1.64	drug target	the enzyme is a potential therapeutic target for hormone-dependent prostate cancer	761168	
1.1.1.64	evolution	the enzyme belongs to the AKR1C subfamily, the members of which catalyze the reduction of ketosteroids and ketoprostaglandins	739797	
1.1.1.64	malfunction	AKR1C3 knockdown is accomplished in cultured adrenal cells (H295R) using small interfering RNA. Decreasing adrenal cell expression of AKR1C3 mRNA and protein inhibit testosterone production in the H295R adrenal cell line	712571	
1.1.1.64	malfunction	enzyme inhibition results in reduced cell proliferation	740162	
1.1.1.64	malfunction	mutations of HSD17B3 genes cause a 46,XY disorder of sexual development (46,XY DSD) as a result of low testosterone production	761760	
1.1.1.64	metabolism	enzyme 17beta-HSD3 acts in the last step of the biosynthesis of testosterone	740162	
1.1.1.64	metabolism	last step of testosterone biosynthesis	761168	
1.1.1.64	metabolism	the enzyme catalyzes the last step in the biosynthesis of the potent androgen testosterone (T), by stereoselectively reducing the C17 ketone of 4-androstene-3,17-dione (4-dione), with NADPH as cofactor	-, 740916	
1.1.1.64	physiological function	AKR1C3 is an important human enzyme that participates in the reduction of steroids and prostaglandins, which leads to proliferative signalling. In addition, this enzyme also participates in the biotransformation of xenobiotics, such as drugs and procarcinogens. AKR1C3 is involved in the development of both hormone-dependent and hormone-independent cancers and confers cell resistance to anthracyclines. Role ofAKR1C3in hormone-dependent (e.g., breast, prostate and endometrium) and hormone-independent (e.g., lung, brain, and kidney) cancers	740912